Register for our free email digests:
Sanofi
https://www.sanofi.com//
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Ablynx N.V.
- Acambis PLC
- Bioverativ Inc. (True North Therapeutics, Inc.)
- BiPar Sciences Inc.
- BMP Sunstone Corporation
- Canderm Pharma Inc.
- Chattem, Inc.
- Connaught Laboratories Ltd.
- Fisons Ltd.
- Fovea Pharmaceuticals, SA
- Genfar S.A.
- Genzyme Corporation
- Groupe Sanofi
- Hoechst Marion Roussel
- Pluromed
- Protein Sciences Corporation
- Rhone-Poulenc Rorer
- Sanofi-Aventis
- Sanofi-aventis Groupe
- Sanofi Pasteur MSD
- Shantha
- Synthorx, Inc. (THOR)
- TargeGen, Inc.
- Thunder Acquisition